Background and Purpose-Risks and benefits of intravenous thrombolysis for patients with stroke Ͼ80 years of age are unclear. We examined outcomes and symptomatic intracerebral hemorrhage rates in Յ80-and Ͼ80-year-old patients in the Safe Implementation of 
T hrombolysis for ischemic stroke represents an important therapeutic advance. However, the completed randomized clinical trials of alteplase for ischemic stroke have included very limited numbers of patients aged Ͼ80 years. Of the trials included in the individual patient meta-analysis, only the National Institute of Neurological Disorders and Stroke (NINDS) had no age limit of 80 years. 1 The European Cooperative Acute Stroke Study (ECASS) trials specifically excluded this age group. 2, 3 As a consequence, the license for alteplase in the European Union is restricted to patients not Ͼ80 years. Data on the safety and efficacy of thrombolysis in the Ͼ80 years population are limited, yet given that this age group already accounts for almost one third of stroke admissions in developed countries, reliable data are needed to enable treatment to be offered to appropriately selected older people and improve the very poor outcomes from stroke seen in this group. 4 Aging demographics and better prevention measures in a middle-aged population are likely to lead to an increasing proportion of admitted patients with patients being Ͼ80 years of age. Several small studies have reported outcomes from older patients with stroke treated with thrombolysis. We determined in the very large Safe Implementation of Treatment in Stroke-International Stroke Thrombolysis Register (SITS-ISTR) database the outcomes and complications seen in patients Ͼ80 years compared with younger patients. 5 
Methods
We analyzed data collected in the SITS-ISTR. 6 The methods of data collection have been described in detail elsewhere. 5 Data were collected across 31 countries worldwide from a total of 476 centers. New centers were defined as centers that had not participated in the ECASS I or II studies or did not treat at least 5 patients before joining SITS. Patients with acute ischemic stroke were treated with alteplase according to the provisional European license and local regulatory requirements. Patients who were treated with license protocol violations, other than age Ͼ80 years, were excluded from the analysis. The following patients were excluded due to protocol violation. One patient may have Ͼ1 exclusion criteria: stroke onset to recombinant tissue plasminogen activator treatment time Ͼ3 hours (nϭ3081), previous stroke within 3 months (nϭ386), previous stroke earlier than 3 months and history of diabetes mellitus and modified Rankin Scale Ն1 (nϭ159), anticoagulants with high-dose heparin that alters activated partial thromboplastin time or oral anticoagulation at stroke onset (nϭ468), blood glucose before treatment Ͻ50 or Ͼ400 mg/dL (2.7 to 22.2 mmol/L; nϭ232), baseline National Institutes of Health Stroke Scale (NIHSS) Ͼ25 (nϭ411), systolic blood pressure Ͼ185 mm Hg (nϭ606), diastolic blood pressure Ͼ110 mm Hg (nϭ253), and patients with missing data (nϭ1454). Patient baseline characteristics, including stroke severity using the NIHSS and prestroke disability and modified Rankin Scale (mRS) score, were recorded. NIHSS was again recorded at 2 and 24 hours after treatment. Outcomes were assessed by 3-month mRS score. All patients underwent brain imaging before treatment and follow-up CT brain imaging was performed at 24 to 36 hours to assess for hemorrhagic transformation. Baseline and follow-up CT scans were reviewed centrally in patients who experienced neurological deterioration or died. Hemorrhagic transformation was categorized using the ECASS trial definitions into hemorrhagic infarction (HI1, HI2), parenchymal hemorrhage (PH1, PH2), and remote parenchymal hemorrhage (PHr1, PHr2). 2 Symptomatic hemorrhage was defined using both the SITS-MOST 5 (Ն4-point increase in NIHSS from baseline or death within 36 hours and PH2 or PHr2 hemorrhage) and NINDS 1 (any increase in NIHSS from baseline and any parenchymal intracerebral hemorrhage) definitions. Patients were divided into 2 groups: Ͼ80 years and Յ80 years. Baseline characteristics, 90-day mortality, and disability (mRS) and complications were compared between the 2 groups. Because increasing age up to 80 years is known to be associated with an increased risk of intracerebral hemorrhage, in a post hoc analysis, symptomatic intracerebral hemorrhage (SICH) rates, mortality, and disability were determined in the age ranges Ͻ60, 61 to 70, 71 to 80, 81 to 90, and Ͼ90 years.
Statistical Analysis
Descriptive statistics for the baseline and demographic data are presented according to the 2 groups Ͼ80 years and Յ80 years. Unknown values were excluded from the denominator when calculating proportions, as previously described. 5, 7, 8 Multivariable logistic regression analyses were performed in an explorative manner to examine if the outcomes differ between the 2 age groups and to find predictors for the main outcomes in the Ͼ80 years group. All variables of interest were included in the analysis. For each main outcome, a backward stepwise procedure was performed using PϾ0.05 of the likelihood ratio test for exclusion. The variables included for each respective outcome were: age group (Ͼ80 years and Յ80 years), gender, diabetes mellitus, hyperlipidemia, atrial fibrillation, congestive heart failure, previous stroke, independency before current stroke measured by mRS 0 to 1, smoking, aspirin treatment at stroke onset, baseline NIHSS, baseline blood glucose and blood pressure, body weight, history of hypertension, signs of current infarction in the baseline imaging study, and stroke onset to treatment time. In the univariate analysis, the upper and lower limits of the CIs used a score method with continuity correction for calculation of the 95% CIs of proportions for SICH, mortality, and independence. 9 All analyses were performed using the STATISTICA software Version 8.0. Multiple analyses were performed by generalized linear or nonlinear model and estimation of OR for dichotomized outcome was calculated using a logistic regression analysis.
Results

Patient Characteristics
Baseline patient characteristics are shown in Table 1 for 1831 patients Ͼ80 years and 19 411 patients Յ80 years. Patients Ͼ80 years had a higher proportion of females; more frequent previous stroke, hypertension, atrial fibrillation, heart failure, and aspirin use on admission; were less likely to be smokers; had higher levels of prestroke disability; increased stroke severity (2-point NIHSS difference); higher systolic blood pressure and blood glucose levels; but had a 5-minute lower median stroke onset to treatment time. The very old group weighed less and received smaller total recombinant tissue plasminogen activator doses and were less likely to be treated in new centers. The Ͼ80 years group had a greater proportion of strokes due to cardiac source of emboli (49.7% versus 31.6%) consistent with the increased average stroke severity.
Outcomes and Complications
Intracranial bleeding rates as determined by CT or MRI findings in the 2 groups are shown in Table 2 . The Ͼ80 years group had a slightly greater rate of remote hemorrhage (Pϭ0.03 for 22-to 36-hour imaging scans and Pϭ0.04 for any posttreatment scans); otherwise, no significant difference was seen between 2 groups. Columns 2 to 4 in Table 3 show the unadjusted outcome and symptomatic hemorrhage complications. The Ͼ80 years group had an increased 3-month mortality rate compared with the Յ80 years group: 30% versus 12% (PϽ0.005), reduced functional independence (mRS 0 to 2) at 3 months: 35% versus 57% (PϽ0.005), and a reduced likelihood of complete recovery at 3 months (mRS 0 to 1): 25% versus 40% (PϽ0.005). Three-month mRS outcomes, including mortality, are shown in Figure 1 . The proportion of patients Ͼ80 years surviving with significant disability (mRS 3 to 5) was the same as for a 71-to 80-year-old group (35% versus 33%).
According to the investigator's judgment, intracerebral hemorrhage was the primary cause of death for 24 of 1831 ( Because increasing age up to 80 years is known to be associated with an increased risk of intracerebral hemorrhage, SICH rates were determined in the age ranges Ͻ60, 61 to 70, 71 to 80, 81 to 90, and Ͼ90 years ( Figure 2 ). No significant difference was seen between SICH rates in 81 to 90 year olds compared with 71 to 80 years (Pϭ0.22 per SITS-MOST definition and Pϭ0.68 per NINDS definition) and there was no trend toward an increased PH2 or SICH rate in the Ͼ90 years group compared with the 71-to 80-year-old group. Mortality and mRS outcomes at 3 months are shown for each age range in Figure 3 . There was a progressive increase in mortality and fewer good outcomes with increasing age.
Multivariate analysis was undertaken to compare outcomes and SICH between the 2 groups adjusting for several baseline prognostically important factors as described in the statistical section (columns 5 to 6 in Table 3 ). After this adjustment, there was no statistically significant difference in SICH rates between patients Ͼ80 years and Յ80 years. OR and 95% CIs Pϭ0.81 for local hemorrhages for protocol adhered; Pϭ0.04 for remote hemorrhages for protocol adhered.
HI 1 indicates hemorrhagic infarct Type 1, small petechiae along the margins of the infarct; HI 2, hemorrhagic infarct Type 2, more confluent petechiae within the infarct area but without space-occupying effect; PH 1, primary intracerebral hemorrhage Type 1, blood clot(s) not exceeding 30% of the infarct area with some mild space-occupying effect; PH 2, primary intracerebral hemorrhage Type 2, blood clots exceeding 30% of the infarct area with significant space-occupying effect; PHr 1, remote primary intracerebral hemorrhage Type 1, small-or medium-sized blood clots located remote from the actual infarct; a mild space-occupying effect could be present; PHr 2, remote primary intracerebral hemorrhage Type 2, large confluent dense blood clots in an area remote from the actual infarct; significant space-occupying effect may be present.
in the Ͼ80 years group compared with Յ80 years for SICH per SITS-MOST definition was 0.90 (0.73 to 1.09; Pϭ0.28) and for SICH per NINDS definition the OR was 0.96 (0.87 to 1.06; Pϭ0.42). There was a statistically significant difference for mortality and functional independence (mRS 0 to 2) at 3 months between the groups. The OR for mortality in the Ͼ80 years group was higher 1.53 (1.43 to 1.65; PϽ0.005) and for independence was lower 0.73 (0.68 to 0.78; PϽ0.005). SICH was not related to older age in multivariate analysis taking into account variables listed in the statistical section and that included previously identified potential risk factors for SICH.
Clinical response to alteplase in each group was also examined by comparing changes in NIHSS at baseline, 2 hours, 24 hours, and 7 days between Յ80-year and Ͼ80-year groups (Figure 4) . The Ͼ80 years group had a higher baseline NIHSS score (14 versus 12) . Both groups had a similar 3-point improvement in NIHSS at 2 hours. At 24 hours and 7 days, the Ͼ80 years had 1 point less improvement in NIHSS (at 24 hours 5 versus 6; at 7 days 7 versus 8). NIHSS scores at baseline, 2 hours, 24 hours, and 7 days differed significantly between Ͼ80 and Յ80 years (PϽ0.005 for all time points). Probability values for NIHSS changes from baseline to 2 hours was 0.14 (by analysis of variance test) and Pϭ0.02 (by Mann-Whitney U test); from baseline to 24 hour and from baseline to 7 days, the probability values were Ͻ0.005 by both methods. The impact of prestroke disability on risk of SICH and 3 months was explored. Prestroke disability (mRS) and SICH per NINDS definition were entered as predictor and their possible interaction for good 3-month outcome (mRS 0 to 2). There was no interaction between these 2 variables with the Յ80 and Ͼ80 years groups.
Discussion
This is the largest prospective observational study of outcomes from thrombolysis in patients Ͼ80 of age and contains 4 times the subjects in the meta-analysis of 6 earlier studies. 10 The main finding of this study is that the overall rate of symptomatic and asymptomatic intracerebral hemorrhage was not increased in the Ͼ80-year-old group. Although the mortality rate is higher in the Ͼ80s compared with younger patients, the proportion of survivors with unfavorable functional outcome (mRS 3 to 5) after thrombolysis was not essentially different between 71-to 80-and 81-to 90-year age bands.
The analysis in 10-year age bands indicates a progressive risk of SICH at each age band between Ͻ60 and 80 years with no difference between 71-to 80-and 81-to 90-year age bands using the SITS-MOST definition. Although patients Ͻ60 years have a lower risk of SICH than those Ͼ70 years, our data do not suggest patients aged 81 to 90 years without major comorbidities have any appreciable increase in the risk of SICH compared with those 71 to 80 years. Data in the Ͼ90-year-old group are limited, but the risk of SICH using the SITS-MOST definition may be even less in this age group presumably because clinicians are using very tight selection criteria when treating this age group. However, using the NINDS definition, there was a trend to an increased risk in the Ͼ90-year-old group. These results are consistent with previous observations in which no differences in SICH rates were reported between patients Ͼ80 and Յ80 years. [11] [12] [13] Comparison of our results with a meta-analysis of 6 studies 10 shows very similar outcome for mortality (30% versus 31%) and good outcome mRS of 0 to 1 (25% versus 26%). However, unlike the meta-analysis, we found no increase in SICH for the Ͼ80 year olds. Although an increased risk of SICH was reported in the meta-analysis (adjusted OR, 1.22), SICH was defined in different ways in the studies and is difficult to interpret.
The less good outcomes seen with respect to mortality and independence in those Ͼ80 years cannot be due to SICH or other complications of thrombolysis, but are due to death from other causes, in particular pneumonia and other complications of stroke. The greater stroke severity, increased prestroke dependency, and frequency of atrial fibrillation and heart failure are factors that contribute to the increased mortality in those Ͼ80 years. The mortality rate reported here is consistent with the high mortality rates reported in very old patients with moderately severe strokes not receiving thrombolysis. The Copenhagen Stroke Study reported an in-hospital mortality of 35% in Ͼ85 year olds. 14 Early changes in NIHSS were similar between Ͼ80 and Յ80 year olds suggesting there was no major difference in the recanalization rate in both groups. This is consistent with a study, 15 which reported a similar proportion of Ͼ80s experienced successful recanalization with intra-arterial therapy.
We undertook multivariable analysis of SICH risk to adjust for the numerous differences in potential confounders at baseline between patients Յ80 years and Ͼ80 years. Previous stroke, congestive heart failure, atrial fibrillation, aspirin therapy, high blood pressure, high blood glucose, and severe stroke (NIHSS score) at baseline were more common or higher in patients Ͼ80 years compared with younger patients and probably explain the higher SICH rates in the Ͼ80-year cohort as defined by NINDS seen in the univariate analysis. The association was not significant after adjustment for these baseline imbalances. Cigarette smoking, which has been found to be negatively associated with the risk of intracerebral hemorrhage in some previous studies was less common among those Ͼ80s. Signs of current infarction on baseline imaging, as reported by the treating clinician, were similar in both groups.
The high levels of prestroke complete functional independence (mRS 0 to 1) in the Ͼ80 year olds in this cohort suggest significant selection of patients Ͼ80 years for treatment. Similar selection processes apply to younger patients, but the prevalence of absolute and relative contraindications to treatment is greater in those Ͼ80s. The safety of thrombolysis in patients Ͼ80 years who have significant prestroke dependency or do not fulfill the other license criteria is unclear, and the results of this study should not be extrapolated to such groups of patients. However, multivariable analysis of the influence of prestroke functional dependency on SICH found that prestroke mRS of 2 to 5 was not associated with an increased risk of SICH. We observed a progressive reduction in good outcomes with increasing age, a consistent finding in other studies on outcome in stroke treated with or without thrombolysis. 10, 11 The poor outcome in patients Ͼ80 years treated with thrombolysis does not mean thrombolysis is ineffective in this age group. The lack of an increase in SICH in the 81-to 90-year age band suggests thrombolysis is likely to be as clinically effective in Ͼ80 year olds in terms of absolute benefits compared with no treatment. However, in clinical practice, the smaller proportion of patients achieving a good outcome in Ͼ80 years may lead to clinicians underestimating the benefits in this group and conversely overestimating the benefits of thrombolysis in younger patients.
This study shows the value of prospective Phase IV studies in defining the risks of therapy in those Ͼ80 years. The size of the study and broad basis mean the results are robust and reliable and suggest that thrombolysis is an appropriate treatment for carefully selected patients Ͼ80 years that can be given without concerns that there is any clinically significant increased risk of SICH. The exact risk benefit of thrombolysis in those Ͼ80 can only be determined from randomized trials, but the early improvement in neurological impairment suggests it is likely patients Ͼ80 years have a similar extent of successful reperfusion as younger patients. The ongoing Thrombolysis in Elderly Stroke Patients and Third International Stroke Trials will provide more data on the risks and benefits of thrombolysis in a broader range of patients with stroke Ͼ80 years in which clinicians remain uncertain whether thrombolysis is indicated. 16, 17 Figure 4. Median (square), interquartile range (rectangle), minimum, and maximum range (whiskers) of NIHSS score changes from baseline to 7 days.
